Mark Schoenberg - 31 Jan 2022 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role: Chief Medical Officer
Signature: /s/ Jason Smith, Attorney-in-Fact
Issuer symbol: URGN
Transactions as of: 31 Jan 2022
Net transactions value: -$10,415
Form type: 4
Filing time: 02 Feb 2022, 15:33:42 UTC
Previous filing: 28 Jan 2022
Next filing: 03 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	URGN	Ordinary Shares	Options Exercise		+500	+2.3%		22,595	31 Jan 2022	Direct	F1
transaction	URGN	Ordinary Shares	Sale	$2,084	-275	-1.2%	$7.58	22,320	31 Jan 2022	Direct	F2
transaction	URGN	Ordinary Shares	Options Exercise		+2,000	+9%		24,320	31 Jan 2022	Direct	F1
transaction	URGN	Ordinary Shares	Sale	$8,330	-1,099	-4.5%	$7.58	23,221	31 Jan 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	URGN	Restricted Stock Units	Options Exercise	$0	-500	-20%	$0.000000	2,000	31 Jan 2022	Ordinary Shares	500		Direct	F1, F3
transaction	URGN	Stock Option (right to buy)	Award	$0	+12,064		$0.000000	12,064	31 Jan 2022	Ordinary Shares	12,064	$7.72	Direct	F4
transaction	URGN	Restricted Stock Units	Award	$0	+4,000		$0.000000	4,000	31 Jan 2022	Ordinary Shares	0		Direct	F1, F5
transaction	URGN	Restricted Stock	Options Exercise	$0	-2,000	-33%	$0.000000	4,000	31 Jan 2022	Ordinary Shares	2,000		Direct	F1, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
F2	Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
F3	The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.
F4	1/3 of the shares underlying the stock options will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025
F5	1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025
F6	The reporting person was granted RSUs on January 31, 2021 representing 6,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022.